ASX-LISTED biopharmaceutical company Zelda Therapeutics is broadening its research to include diabetes related cognitive decline.
Working with the Curtin Health Innovation Research Institute at Curtin University, Zelda said it will study "the effect of a cannabinoid-based therapeutic moderating the effects of cerebral capillary damage associated with diabetes".
The risk of developing dementia for people with diabetes is almost three times greater than the normal healthy population, the company said, and well-validated animal models of diabetic cognitive decline developed by Curtin University will be studied by a team led by NHMRC's Dementia Leadership Research Fellow Associate Professor Ryu Takechi.
The commercialisation potential for any prophylactic therapeutic intervention arising from the research could reach US$1 trillion.
Last month Zelda also expanded its pre-clinical trial for pancreatic cancer with Curtin University.
The above article was sent to subscribers in Pharmacy Daily's issue from 19 Apr 18
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 19 Apr 18
